SIDEBAR
»
S
I
D
E
B
A
R
«
AstraZeneca-Arbitrage Possibilities
May 13th, 2014 by hackel

The clear rejection by the Board of AstraZeneca to Pfizer may not necessarily mean a permanent end to a deal. This reports reveals what the Board needs to hear and the possibility of such taking place.

 

This report available to consulting clients of CT Capital LLC. Contact kenhackel@ctcapllc.com or gailtrokie@ctcapllc.com for information


Comments are closed

SIDEBAR
»
S
I
D
E
B
A
R
«
»  Substance:WordPress   »  Style:Ahren Ahimsa